Scilex Holding Company To Present "Prophylaxis Of Gout Flares In Patients With Renal Impairment: Dosing Adjustments With Colchicine Oral Solution Informed By A Pharmacokinetic Model" At The 2024 American College Of Rheumatology Convergence Conference In Washington, D.C. On November 14 – 19, 2024

Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the acceptance of a presentation at the 2024 American College of Rheumatology Convergence conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024.

Title: Prophylaxis of Gout Flares in Patients with Renal Impairment: Dosing Adjustments with Colchicine Oral Solution Informed by a Pharmacokinetic Model

Authors: Jaymin Shah, PhD, FCP; Elaine K. Chan, PharmD; Dmitri Lissin, MD

Presentation: Saturday, November 16, 2024, at 10:30 AM ET - 12:30 PM ET

• GLOPERBA (colchicine oral solution) is the first and only liquid formulation of colchicine that offers precision dosing for at risk gout patients.
• Scilex recently received FDA approval for an updated GLOPERBA label, which reflects dosing adjustments in various clinical situations. Unlike other colchicine formulations, GLOPERBA allows reduction of daily dose in patients with severe renal impairment (0.3 mg/day).
  • Data to be presented summarizes pharmacokinetic model derived dosing for at-risk moderate and severe chronic kidney disease patients who require lower precision dosing, not offered by other colchicine formulations of tablets and capsules currently available on the market.